ATE364096T1 - Verfahren zur diagnose und therapie von schizophrenie - Google Patents

Verfahren zur diagnose und therapie von schizophrenie

Info

Publication number: ATE364096T1
Authority: AT; Austria
Prior art keywords: gene encoding; genes; screening; methods; transgenic nonhuman
Prior art date: 2002-03-20

Application number

AT03714858T

Other languages

English (en)

Inventor

Francis Buxton

William Carpenter

Rosalinda Roberts

Carol Tamminga

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-20

Filing date

2003-03-19

Publication date

2007-06-15

2003-03-19 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE364096T1 publication Critical patent/ATE364096T1/de

Links

238000000034 method Methods 0.000 title abstract 3
201000000980 schizophrenia Diseases 0.000 title abstract 2
238000003745 diagnosis Methods 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
108090000623 proteins and genes Proteins 0.000 abstract 5
101000806511 Homo sapiens Protein DEPP1 Proteins 0.000 abstract 2
241001465754 Metazoa Species 0.000 abstract 2
102100037469 Protein DEPP1 Human genes 0.000 abstract 2
238000012216 screening Methods 0.000 abstract 2
230000009261 transgenic effect Effects 0.000 abstract 2
102000004379 Adrenomedullin Human genes 0.000 abstract 1
101800004616 Adrenomedullin Proteins 0.000 abstract 1
101100018293 Clostridioides difficile pflE gene Proteins 0.000 abstract 1
101000823782 Homo sapiens Y-box-binding protein 3 Proteins 0.000 abstract 1
102100022221 Y-box-binding protein 3 Human genes 0.000 abstract 1
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 abstract 1
101150008232 csdA gene Proteins 0.000 abstract 1
101150077693 deaD gene Proteins 0.000 abstract 1
229940124606 potential therapeutic agent Drugs 0.000 abstract 1
230000000698 schizophrenic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Pathology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Laser Surgery Devices (AREA)

AT03714858T 2002-03-20 2003-03-19 Verfahren zur diagnose und therapie von schizophrenie ATE364096T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36600102P	2002-03-20	2002-03-20

Publications (1)

Publication Number	Publication Date
ATE364096T1 true ATE364096T1 (de)	2007-06-15

Family

ID=28042049

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03714858T ATE364096T1 (de)	2002-03-20	2003-03-19	Verfahren zur diagnose und therapie von schizophrenie

Country Status (7)

Country	Link
US (1)	US20050227233A1 (de)
EP (1)	EP1487998B1 (de)
JP (1)	JP2005520521A (de)
AT (1)	ATE364096T1 (de)
AU (1)	AU2003219085A1 (de)
DE (1)	DE60314236T2 (de)
WO (1)	WO2003078658A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070015152A1 (en) *	2002-12-12	2007-01-18	Novartis Ag	Methods for diagnosing and treating schizophrenia
US20040210159A1 (en) *	2003-04-15	2004-10-21	Osman Kibar	Determining a psychological state of a subject
DE102005036094A1 (de) *	2005-08-01	2007-02-08	B.R.A.H.M.S Ag	In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US20080075789A1 (en) *	2006-02-28	2008-03-27	The Regents Of The University Of California	Genes differentially expressed in bipolar disorder and/or schizophrenia
US20100070186A1 (en) *	2006-03-15	2010-03-18	Soper Bryan R	Methods of screening for and mapping phenotypic and genotypic variations in cells
KR100783670B1 (ko)	2006-05-22	2007-12-07	한국표준과학연구원	도메인 단백질을 이용한 생리활성물질의 검색 방법
KR101464397B1 (ko)	2007-03-29	2014-11-28	더 닐슨 컴퍼니 (유에스) 엘엘씨	마케팅 및 엔터테인먼트 효과의 분석
US9886981B2 (en)	2007-05-01	2018-02-06	The Nielsen Company (Us), Llc	Neuro-feedback based stimulus compression device
US8386312B2 (en) *	2007-05-01	2013-02-26	The Nielsen Company (Us), Llc	Neuro-informatics repository system
US8392253B2 (en)	2007-05-16	2013-03-05	The Nielsen Company (Us), Llc	Neuro-physiology and neuro-behavioral based stimulus targeting system
US8494905B2 (en) *	2007-06-06	2013-07-23	The Nielsen Company (Us), Llc	Audience response analysis using simultaneous electroencephalography (EEG) and functional magnetic resonance imaging (fMRI)
KR20100038107A (ko)	2007-07-30	2010-04-12	뉴로포커스, 인크.	신경-반응 자극 및 자극 속성 공명 추정기
KR20100047865A (ko) *	2007-08-28	2010-05-10	뉴로포커스, 인크.	소비자 경험 평가 시스템
US8635105B2 (en) *	2007-08-28	2014-01-21	The Nielsen Company (Us), Llc	Consumer experience portrayal effectiveness assessment system
US8386313B2 (en) *	2007-08-28	2013-02-26	The Nielsen Company (Us), Llc	Stimulus placement system using subject neuro-response measurements
US8392255B2 (en)	2007-08-29	2013-03-05	The Nielsen Company (Us), Llc	Content based selection and meta tagging of advertisement breaks
US20090083129A1 (en)	2007-09-20	2009-03-26	Neurofocus, Inc.	Personalized content delivery using neuro-response priming data
US8494610B2 (en)	2007-09-20	2013-07-23	The Nielsen Company (Us), Llc	Analysis of marketing and entertainment effectiveness using magnetoencephalography
MX2010003371A (es)	2007-09-28	2010-05-05	Intrexon Corp	Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
EP2321417B1 (de) *	2008-08-20	2015-07-15	Brainco Biopharma, S.L.	Stxbp1 als psychiatrischer biomarker im mausmodellsystem und deren anwendungen
US9077699B1 (en) *	2008-09-11	2015-07-07	Bank Of America Corporation	Text chat
US8271509B2 (en) *	2008-11-20	2012-09-18	Bank Of America Corporation	Search and chat integration system
US9357240B2 (en)	2009-01-21	2016-05-31	The Nielsen Company (Us), Llc	Methods and apparatus for providing alternate media for video decoders
US8464288B2 (en)	2009-01-21	2013-06-11	The Nielsen Company (Us), Llc	Methods and apparatus for providing personalized media in video
US8270814B2 (en)	2009-01-21	2012-09-18	The Nielsen Company (Us), Llc	Methods and apparatus for providing video with embedded media
US20100250325A1 (en)	2009-03-24	2010-09-30	Neurofocus, Inc.	Neurological profiles for market matching and stimulus presentation
US8655437B2 (en)	2009-08-21	2014-02-18	The Nielsen Company (Us), Llc	Analysis of the mirror neuron system for evaluation of stimulus
US10987015B2 (en)	2009-08-24	2021-04-27	Nielsen Consumer Llc	Dry electrodes for electroencephalography
US20110106750A1 (en)	2009-10-29	2011-05-05	Neurofocus, Inc.	Generating ratings predictions using neuro-response data
US8209224B2 (en)	2009-10-29	2012-06-26	The Nielsen Company (Us), Llc	Intracluster content management using neuro-response priming data
US9560984B2 (en)	2009-10-29	2017-02-07	The Nielsen Company (Us), Llc	Analysis of controlled and automatic attention for introduction of stimulus material
US8335715B2 (en)	2009-11-19	2012-12-18	The Nielsen Company (Us), Llc.	Advertisement exchange using neuro-response data
US8335716B2 (en)	2009-11-19	2012-12-18	The Nielsen Company (Us), Llc.	Multimedia advertisement exchange
US8684742B2 (en)	2010-04-19	2014-04-01	Innerscope Research, Inc.	Short imagery task (SIT) research method
US8655428B2 (en)	2010-05-12	2014-02-18	The Nielsen Company (Us), Llc	Neuro-response data synchronization
US8392250B2 (en)	2010-08-09	2013-03-05	The Nielsen Company (Us), Llc	Neuro-response evaluated stimulus in virtual reality environments
US8392251B2 (en)	2010-08-09	2013-03-05	The Nielsen Company (Us), Llc	Location aware presentation of stimulus material
US8396744B2 (en)	2010-08-25	2013-03-12	The Nielsen Company (Us), Llc	Effective virtual reality environments for presentation of marketing materials
US9451303B2 (en)	2012-02-27	2016-09-20	The Nielsen Company (Us), Llc	Method and system for gathering and computing an audience's neurologically-based reactions in a distributed framework involving remote storage and computing
US9292858B2 (en)	2012-02-27	2016-03-22	The Nielsen Company (Us), Llc	Data collection system for aggregating biologically based measures in asynchronous geographically distributed public environments
US9569986B2 (en)	2012-02-27	2017-02-14	The Nielsen Company (Us), Llc	System and method for gathering and analyzing biometric user feedback for use in social media and advertising applications
US9060671B2 (en)	2012-08-17	2015-06-23	The Nielsen Company (Us), Llc	Systems and methods to gather and analyze electroencephalographic data
US9320450B2 (en)	2013-03-14	2016-04-26	The Nielsen Company (Us), Llc	Methods and apparatus to gather and analyze electroencephalographic data
US9622702B2 (en)	2014-04-03	2017-04-18	The Nielsen Company (Us), Llc	Methods and apparatus to gather and analyze electroencephalographic data
US9936250B2 (en)	2015-05-19	2018-04-03	The Nielsen Company (Us), Llc	Methods and apparatus to adjust content presented to an individual
CN105671066B (zh) *	2016-03-03	2019-06-14	中国药科大学	一种调节人结肠肿瘤细胞的表达载体、制备方法及其应用
ES2688737A1 (es) *	2017-05-04	2018-11-06	Universidad Del País Vasco / Euskal Herriko Unibertsitatea	Método para diagnosticar placa ateroesclerótica inestable

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2242308A1 (en) *	1997-12-08	1999-06-08	Smithkline Beecham Laboratoires Pharmaceutiques	Novel compounds
WO2001064835A2 (en) *	2000-02-28	2001-09-07	Hyseq, Inc.	Novel nucleic acids and polypeptides
EP1276751A4 (de) *	2000-02-28	2005-04-06	Nuvelo Inc	Neue nukleinsäuren und polypeptide

2003
- 2003-03-19 WO PCT/EP2003/002875 patent/WO2003078658A2/en not_active Ceased
- 2003-03-19 EP EP03714858A patent/EP1487998B1/de not_active Expired - Lifetime
- 2003-03-19 AU AU2003219085A patent/AU2003219085A1/en not_active Abandoned
- 2003-03-19 AT AT03714858T patent/ATE364096T1/de not_active IP Right Cessation
- 2003-03-19 JP JP2003576650A patent/JP2005520521A/ja active Pending
- 2003-03-19 DE DE60314236T patent/DE60314236T2/de not_active Expired - Fee Related
- 2003-03-19 US US10/507,858 patent/US20050227233A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20050227233A1 (en)	2005-10-13
EP1487998A2 (de)	2004-12-22
JP2005520521A (ja)	2005-07-14
DE60314236T2 (de)	2008-02-14
DE60314236D1 (de)	2007-07-19
EP1487998B1 (de)	2007-06-06
WO2003078658A3 (en)	2004-02-19
WO2003078658A2 (en)	2003-09-25
AU2003219085A1 (en)	2003-09-29

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1487998

Country of ref document: EP

2010-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60314236D1 (de)	2007-07-19	Verfahren zur diagnose und therapie von schizophrenie
Zheng et al.	2021	Electroacupuncture ameliorates beta-amyloid pathology and cognitive impairment in Alzheimer disease via a novel mechanism involving activation of TFEB (transcription factor EB)
Steinberg et al.	2014	Positive reinforcement mediated by midbrain dopamine neurons requires D1 and D2 receptor activation in the nucleus accumbens
Wang et al.	2020	Direct septum-hippocampus cholinergic circuit attenuates seizure through driving somatostatin inhibition
Brown et al.	2010	Melanopsin contributions to irradiance coding in the thalamo-cortical visual system
Abs et al.	2018	Learning-related plasticity in dendrite-targeting layer 1 interneurons
Fougère et al.	2021	Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson’s disease
Conner et al.	2003	Lesions of the basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning
Bogdanik et al.	2015	Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy
Semo et al.	2010	Dissecting a role for melanopsin in behavioural light aversion reveals a response independent of conventional photoreception
KR20180085773A (ko)	2018-07-27	치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법
Liu et al.	2019	Malocclusion generates anxiety-like behavior through a putative lateral Habenula–mesencephalic trigeminal nucleus pathway
Wang et al.	2014	Optogenetic activation of GABAergic neurons in the nucleus accumbens decreases the activity of the ventral pallidum and the expression of cocaine-context-associated memory
Blasi et al.	2015	Lasting pure-motor deficits after focal posterior internal capsule white-matter infarcts in rats
Gao et al.	2021	Blockade of Indoleamine 2, 3-dioxygenase 1 ameliorates hippocampal neurogenesis and BOLD-fMRI signals in chronic stress precipitated depression
de Oliveira et al.	2021	Lost in translation: no effect of repeated optogenetic cortico-striatal stimulation on compulsivity in rats
Ji et al.	2022	Activation of the VpdmVGLUT1-VPM pathway contributes to anxiety-like behaviors induced by malocclusion
Upton et al.	2023	Right inferior frontal gyrus theta-burst stimulation reduces smoking behaviors and strengthens fronto-striatal-limbic resting-state functional connectivity: a randomized crossover trial
Barker et al.	2023	Lateral preoptic area glutamate neurons relay nociceptive information to the ventral tegmental area
Bulk et al.	2025	A food-sensitive olfactory circuit drives anticipatory satiety
Kang et al.	2025	Repetitive Transcranial Magnetic Stimulation Induces Cognitive Recovery in Alzheimer's Disease via GABAergic Neuron Activation of the Cx3cl1‐Cx3cr1 Axis
Dong et al.	2025	Molecularly distinct striatonigral neuron subtypes differentially regulate locomotion
Fan et al.	2019	Optogenetic inhibition of ventral hippocampal neurons alleviates associative motor learning dysfunction in a rodent model of schizophrenia
Guo et al.	2020	Fos‐CreER‐based genetic mapping of forebrain regions activated by acupuncture
İzci et al.	2022	Neurobiology and genetics of behavioral addictions: A brief review